USGI Medical Receives IDE To Test Incisionless Weight Loss Procedure
This article was originally published in The Gray Sheet
Executive Summary
USGI Medical received a conditional investigational device exemption from FDA to test its catheter for treating obesity using an incisionless, endoscopic procedure.
You may also be interested in...
Obesity 2015: Less Invasive Options Will Drive Growth In Market Hungry For Solutions
Nearly half of the world’s adult population will be overweight or obese by 2030 and obesity is tied to more than 40 diseases. Enterprising companies are heeding the call with increasingly less invasive weight loss devices, while an amenable regulatory environment means the marketplace will welcome some of these innovations in 2015.
Obesity Intervention: A New Era Of Discovery And Innovation
Driven by a vast and underserved market in dire need of safer, less-invasive, more effective solutions, manufacturers are developing several next-generation devices for the minimally invasive treatment of obesity. Many of these emerging devices not only mimic the restriction and malabsorption mechanisms involved in bariatric surgery, but are also designed to influence the metabolic responses that are key to losing weight, improving outcomes, and impacting chronic disease. Indeed the obesity intervention paradigm is rapidly changing as ongoing research provides new insights into the underlying mechanisms behind obesity and bariatric surgery, heralding a new era where the primary treatment target for bariatric surgery is becoming disease specific, rather than targeted at obesity alone.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”